SAN FRANCISCO — Element Science, developer of the Jewel Patch Wearable Cardioverter Defibrillator, has expanded its executive leadership team with several appointments aimed at supporting commercialization and the company’s next phase of growth.
The company named Paul Mandina as Chief Revenue Officer, Mark Hughes as Chief Operating Officer, Eric Samuels as Chief Financial Officer, and Cheeka Trikha as Head of People and Organization.
“Element Science is entering an exciting new phase as we build the organization to support the commercialization of the Jewel Patch, and position the company for its next stage of growth,” said Doug Devine, Chief Executive Officer of Element Science. “These appointments reflect our continued investment in building a world-class leadership team with the expertise needed to execute our strategy.”
Paul Mandina brings more than 20 years of medtech commercial leadership experience. He most recently served as Vice President of U.S. Sales at Medtronic, where he led a $500 million portfolio. He previously held roles at Nevro, St. Jude Medical and Intuitive Surgical. At Element Science, Mandina will help shape commercial strategy and support market expansion.
Mark Hughes joins from iRhythm, where he led operations during a period of commercial scaling. Element Science said his manufacturing and supply chain experience will support the company’s early U.S. commercialization efforts.
Eric Samuels brings financial and operational experience from previous leadership roles at iRhythm and Intel. As Chief Financial Officer, he will oversee the company’s financial and operational infrastructure as Element Science prepares for long-term growth.
Cheeka Trikha joins from Cognite, where she led People Business Partnering. She previously held senior human resources roles at SAP, iRhythm and Confluent. Element Science said she will focus on organizational development and expansion of the company’s workforce.
Element Science’s Jewel Patch is a wearable cardioverter defibrillator designed to monitor and protect patients at high risk of sudden cardiac arrest. The company said the new executive appointments are intended to strengthen its commercial, operational, financial and organizational capabilities as it works to expand access to the device.
